New In Vivo Syngeneic Glioblastoma Mouse Model – Shuttle Session
05 / 23 / 2018
To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-June, 2018. In this session, only experimental test groups-related costs will be covered by Sponsors ; control groups being supported by Explicyte.